Cullinan Therapeutics (CGEM) Net Cash Flow (2020 - 2026)

Cullinan Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$13.3 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 108.68% year-over-year to -$13.3 million in Q1 2026; TTM through Mar 2026 was -$1.6 million, a 164.85% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, up 134.53% from the prior year.
• Net Cash Flow improved to -$13.3 million in Q1 2026 per CGEM's latest filing, from -$15.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $277.4 million in Q2 2022 and bottomed at -$110.9 million in Q3 2022.
• The 5-year median for Net Cash Flow is -$12.9 million (2024), against an average of $900411.8.
• Across the five-year window, Net Cash Flow tumbled 308.17% in 2023 and surged 335.89% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$86.5 million in 2022, then soared by 138.83% to $33.6 million in 2023, then plunged by 156.81% to -$19.1 million in 2024, then climbed by 21.37% to -$15.0 million in 2025, then climbed by 11.68% to -$13.3 million in 2026.
• Per Business Quant, the three latest CGEM Net Cash Flow figures stand at -$13.3 million (Q1 2026), -$15.0 million (Q4 2025), and $30.5 million (Q3 2025).